Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acupuncture for Prevention of Postoperative Nausea and Vomiting (PONV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04866121
Recruitment Status : Recruiting
First Posted : April 29, 2021
Last Update Posted : May 3, 2021
Sponsor:
Information provided by (Responsible Party):
Alirıza Erdoğan, Nigde Omer Halisdemir University

Brief Summary:
The aim of this study is to compare the single point stimulation (P6) and double point stimulation (P6+ST36) performed before anesthesia induction with standard treatment in terms of PONV development and postoperative anti-emetic requirement in patients undergoing laparoscopic cholecystectomy.

Condition or disease Intervention/treatment Phase
PONV Procedure: Acupuncture Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 105 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Comparison of P6+ST36 Combination Acupuncture Therapy With P6 Alone Acupuncture and Standard Treatment in Postoperative Nausea and Vomiting
Actual Study Start Date : May 1, 2021
Estimated Primary Completion Date : May 1, 2022
Estimated Study Completion Date : May 1, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Standard Treatment
Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
Active Comparator: Single point (P6) Acupuncture

Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol to the P6 point bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards.

Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.

Procedure: Acupuncture
A standardized acupuncture protocol will be administered

Experimental: Double point (P6+ST36) Acupuncture
Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol both to the P6 and ST36 points bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For ST6 acupuncture stimulation 0,25x50mm steel needles will be immersed for 5cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards. Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
Procedure: Acupuncture
A standardized acupuncture protocol will be administered




Primary Outcome Measures :
  1. PONV prophylaxis [ Time Frame: 12 months ]
    The frequency of PONV development

  2. Postoperative anti-emetic requirement [ Time Frame: 12 months ]
    The amount of anti-emetic agent administered postoperatively



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Laparoscopic cholecystectomy is performed far more in women than in men with a ratio of 5:1. Additionally, being women is one of the major risk factors for PONV development.
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women between 18-65 years old, who have ASA scores of I-II-III and who are planned to undergo elective laparoscopic cholecystectomy.

Exclusion Criteria:

  • Pregnant women
  • Lactating women
  • Women with steel hypersensitivity
  • Mental retarded patients
  • Patients with psychological disorders and neurologic sequel
  • Additionally, patients who;
  • have nausea/vomiting, consume anti-emetic or emetogenic drugs, alcohol, opioid drugs, glucocorticoid drug and have acupuncture treatment for any reason 72 hours prior to surgery
  • have skin reactions at the site of acupuncture application
  • had intraoperative gangrenous cholecystitis, gall bladder perforation, malignant pathological outcome
  • were admitted to intensive care unite
  • had to convert to open surgery will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04866121


Contacts
Layout table for location contacts
Contact: Alirıza Erdoğan, MD 05333558377 alirizaerdogan@ohu.edu.tr

Locations
Layout table for location information
Turkey
Niğde Ömer Halisdemir University Training and Research Hospital Recruiting
Niğde, Turkey
Contact: Alirıza Erdoğan, MD    05333558377    alirizaerdogan@ohu.edu.tr   
Sponsors and Collaborators
Nigde Omer Halisdemir University
Publications:

Layout table for additonal information
Responsible Party: Alirıza Erdoğan, Principal Investigator, Nigde Omer Halisdemir University
ClinicalTrials.gov Identifier: NCT04866121    
Other Study ID Numbers: 14.04.2021/28
First Posted: April 29, 2021    Key Record Dates
Last Update Posted: May 3, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alirıza Erdoğan, Nigde Omer Halisdemir University:
PONV
P6 Acupuncture
ST36 Acupuncture
Additional relevant MeSH terms:
Layout table for MeSH terms
Vomiting
Postoperative Nausea and Vomiting
Nausea
Signs and Symptoms, Digestive
Postoperative Complications
Pathologic Processes